Sean Scanlan - May 16, 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Innovation Officer
Signature
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Stock symbol
TMCI
Transactions as of
May 16, 2023
Transactions value $
-$633,478
Form type
4
Date filed
5/18/2023, 09:00 PM
Previous filing
Mar 10, 2023
Next filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Options Exercise $2.5K +25K +77.17% $0.10* 57.4K May 16, 2023 Direct F1, F2
transaction TMCI Common Stock Sale -$636K -25K -43.56% $25.44 32.4K May 16, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Options Exercise $0 -25K -42.55% $0.00 33.8K May 16, 2023 Common Stock 25K $0.10 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Includes 31,256 RSUs.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.0600 to $25.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vested in equal annual installments over 4 years, commencing on December 15, 2015 with the last installment vesting on December 15, 2018.